Anti-rejection Drug May Increase Risk of Diabetes After Kidney Transplant, says a study in the July Journal of the American Society of Nephrology (JASN).

The connection between Sirolimus, a new type of anti-rejection drug, and diabetes after transplantation of kidney material was tested and a robust association was found.

Dr. John S. Gill, the professor of University of British Columbia, told that he and his group of scientists tested a large group of kidney transplant recipients in the United States, approximately 20,000 Medicare beneficiaries undergoing kidney transplantation between 1995 and 2003 to find statistically significant result and they did it.

None of the 20,000 patients had diabetes before their kidney transplant. Other potential risk factors were also considered and it appeared that the risk of diabetes was independent of other factors that are known to increase the risk of diabetes.

So, the results proved a higher rate of post-transplant diabetes among patients treated with sirolimus, compared to other anti-rejection drugs – about 30-60%.

Aureon launches a new prostate cancer test called Prostate Px+. To develop this test, Aureon studied data of 1,027 men. The research for the developm...

Recently, in the International Conference of the American Thoracic Society, the representatives of Basilea Pharmaceutica made a presentation of the re...